Navigation Links
BD Board Declares Dividend
Date:5/20/2009

FRANKLIN LAKES, N.J., May 20 /PRNewswire-FirstCall/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 33 cents per common share, payable on June 30, 2009 to holders of record on June 9, 2009. The indicated annual dividend rate is $1.32 per share.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

    Contacts:
    Colleen T. White, Corporate Communications - 201-847-5369
    Patricia A. Spinella, Investor Relations - 201-847-5453

'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Recondo Technology Announces Two New Board Members
2. Digirad Names Two Veteran Healthcare Executives to Board
3. Many Companies Preparing on Global Scale for A(H1N1) Swine Flu Pandemic, According to Global Survey by Councils of The Conference Board
4. Support Bristols Highly Qualified Independent Nominees for Advocat Board
5. InfoGroup Founder and Board Member Criticizes Adoption of Poison Pill
6. Joslin Diabetes Center Names Boston Celtics Star Ray Allen to Board of Trustees
7. WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board
8. XTENT, Inc. Announces Approval of Plan of Liquidation and Dissolution by Board of Directors and Filing of Proxy Materials With the SEC
9. Thoratec Announces Appointment of Paul LaViolette to Board of Directors
10. Martin Crane, M.D., Assumes Chairmanship of the Federation of State Medical Boards
11. Blue Cross Board of Trustees Elects Two New Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... Pekin, IL (PRWEB) , ... June 28, 2017 , ... ... research shows that every 62 minutes, at least one person dies as a direct ... grows, a greater need exists for qualified treatment providers. The iaedp Foundation meets this ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) ... year study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium ... brine-impacted groundwater. As a part of the study, batch adsorption experiments were conducted ...
(Date:6/27/2017)... Fla. (PRWEB) , ... June 27, 2017 , ... ... today announced the appointment of Mike Finnegan to the position of Executive Vice ... years of experience in healthcare technology, telehealth and medical device sales leadership. He ...
(Date:6/27/2017)... ... 27, 2017 , ... The Congressional Budget Office (CBO) projects that the Better ... Patient Protection and Affordable Care Act (ACA), would result in 22 million Americans losing ... law. , More than 20 million Americans have gained health insurance under the ACA, ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... the U.S. Food and Drug Administration (FDA) has notified the ... to its Zhejiang, China manufacturing facility ... "The successful clearance of the Warning Letter related to our ... a measure of the progress we have made in our ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
Breaking Medicine Technology: